AstraZeneca's Farcega Direct to Consumer Ads for CKD

The Filtrate:

Joel Topf

Swapnil Hiremath

Josh Waitzman

Sophia Ambruso

Priya Yenebere

With Special Guest:

Brendon Neuen, Secretariat of the SGLT2 Trialists Consortium and cool guy on Twitter.

Editor:

Sophia Ambruso

Show Notes:

Joel’s Conflict of Interest Statement. Sophia is also conflicted with Astra Zeneca and Brendon with everybody in the SGLT2i space.

Joel starts off with a history of SGLT2i

EMPA-REG Outcomes. First!

CANVAS. OMG this signal is reproducible!

CREDENCE (🎧). It works in a dedicated population at high risk of kidney disease. And in a study designed for renal end-points.

DAPA-CKD (🎧). It’s not just for diabetics!

EMPA-Kidney. It works at really low GFR. And without albuminuria. And again in non-diabetics.

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution

Click to find the supplement (requires a subscription)

Differences in definition in the decreased renal function component of the composite primary outcomes.

EMPA-Kidney 40%

DAPA-Kidney 50%

CREDENCE doubling of serum Cr

Usability Testing of a Sick-Day Protocol in CKD (Pubmed)

New Guidelines for Statistical Reporting in the Journal (link, commentary on said guidelines by Frank Harrell)

CKD outcomes and the FDA: Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

The Peripheral on Amazon Prime

Unsealed the Tylenol Murders Podcast

Project Hail Mary by Andrew Weir

Lizzy McAlpine Singer Song Writer

Rachel Maddow Presents: Ultra

Twitter chaos continues. Get your Med-Mastodon handle